Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer

Exclusion Criteria

• •History of untreated and or progression central nervous system metastases
• •History of another primary cancer except: curatively treated in situ cervical cancer or breast; curatively resected non-melanoma skin cancer; other primary solid tumor curatively treated with no known active disease present and no treatment administered for 3 years or more prior to enrollment
• •Intolerance to cetuximab leading to drug discontinuation due to rash, GI toxicity, or other grade 3 or 4 toxicities
• •Radiotherapy \< 14 days prior to enrollment
• •Systemic chemotherapy, hormonal therapy, immunotherapy, or experimental or approved proteins/antibodies \< 14 days before enrollment
• •Subjects requiring chronic use of immunosuppressive agents
• •Any investigational agent or therapy 30 days prior to enrollment
• •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with any study requirements
• •History of interstitial lung disease
• •Women who test positive for serum or urine pregnancy test or who are breast feeding